The ESC Guidelines on heart failure, sacubitril–valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy
Open Access
- 21 September 2021
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (36), 3581-3585
- https://doi.org/10.1093/eurheartj/ehab627
Abstract
For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts.This publication has 18 references indexed in Scilit:
- Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse modelsEuropean Heart Journal, 2021
- Early invasive coronary angiography and acute ischaemic heart failure outcomesEuropean Heart Journal, 2021
- Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trialEuropean Heart Journal, 2021
- Neuraminidase 1 is a driver of experimental cardiac hypertrophyEuropean Heart Journal, 2021
- Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapiesEuropean Heart Journal, 2021
- Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trialEuropean Heart Journal, 2021
- Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trialEuropean Heart Journal, 2021
- Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)European Heart Journal, 2020
- The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in contextEuropean Heart Journal, 2020
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016